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Abstract 
Type 2 diabetes mellitus is associated with dyslipdemia, insulin resistance and 
non alcoholic fatty liver disease. The purpose of the current study was to assess 
whether type 2 diabetes mellitus-induced hyperglycemia has an effect on the 
lipid profile and release of oxidative stress markers and inflammatory mediators 
in patients with non alcoholic fatty liver disease and normal liver function tests 
which may in turn lead to enhancing the pathogenicity of this liver disease. For 
this purpose, one hundred and five outpatients, matched in age and weight, 
were classified into two groups: the first group consisted of patients with non 
alcoholic fatty liver disease and the second group consisted of patients with non 
alcoholic fatty liver disease in conjunction with hyperglycemia due to the 
presence of type 2 diabetes mellitus. In all patients, lipid profile, oxidative 
stress, and inflammatory mediators were assessed by measuring serum 
concentrations of triglycerides, low density lipoprotein, hydrogen preroxide, 
malondialdehyde, tumor necrosis factor-alpha and interleukin-6, respectively. In 
the studied population, it was found that the presence of type 2 diabetes 
mellitus-induced hyperglycemia significantly impaired lipid profile, and 
significantly enhanced the formation of hydrogen preroxide and malon-
dialdehyde as well as significantly increased the release of tumor necrosis 624  M. E. E. Shams, M. M. H Al-Gayyar, and E. A. M. E. Barakat:   
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factor-alpha and interleukin-6 in the second group of patients. In addition, 
plasma glucose level showed significant positive correlation with hydrogen 
peroxide, malondialdehyde, tumor necrosis factor-alpha and interleukin-6. From 
the previous results, it was concluded that the presence of type 2 diabetes 
mellitus-induced hyperglycemia results in significant increase in lipid profile, 
oxidative stress markers and inflammatory mediators in patients with non 
alcoholic fatty liver disease and normal liver function tests. For this reason, 
further research studies may be essential to evaluate the  benefit of adding 
suitable antioxidant and anti-inflammatory drugs to the treatment regimen for 
this group of patients. In addition, regular monitoring of blood glucose levels and 
liver function tests should be advised to this category of patients to reduce liver 
fat deposition and avoid the development of non alcoholic steatohepatitis, 
cirrhosis or liver cancer and their related complications. 
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Introduction 
Nonalcoholic Fatty Liver Disease (NAFLD) has become a global epidemic, affecting   
20–40% of the general adult population [1]. During the past 20 to 30 years, the frequency 
of patients presenting with NAFLD has increased gradually in proportion to the increase in 
the population with life-style related diseases [2]. A recent study in Japan showed that 
approximately 20 to 25% of diabetic patients showed NAFLD [3]. Nonalcoholic fatty liver 
disease represents a spectrum  of disorders characterized by predominantly macro-
vesicular hepatic steatosis that occur in individuals even in the absence of consumption of 
alcohol in amounts considered harmful to the liver [1]. The likelihood of having NAFLD is 
directly proportional to body weight and presence of diabetes mellitus (DM) [4]. Most 
individuals who are suffering from NAFLD in its uncomplicated form are asymptomatic [5]. 
However, a subset progresses to more severe manifestations of the NAFLD disease 
spectrum may occur, including nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis and 
liver failure [6, 7]. 
It is estimated also that 75% of type 2 diabetic patients (T2DM) present some form of 
NAFLD of different degrees. It is ranging from simple fatty liver (steatosis), to nonalcoholic 
steatohepatitis (NASH), to cirrhosis (irreversible, advanced scarring of the liver). All of the 
stages of NAFLD have in common the accumulation of fat (fatty infiltration) in the liver cells 
(hepatocytes). In  NASH, the fat accumulation is associated with varying degrees of 
inflammation (hepatitis) and scarring (fibrosis) of the liver [8]. 
Type 2 diabetes mellitus enhances lipolysis and inhibits glucose uptake thus increasing 
triglyceride (TG) formation by adipose tissue [9]. Adipose tissue has  currently been 
regarded as an active player in the regulation of metabolism since the discovery of several 
adipocyte-derived factors, collectively known as adipokines. In this context, numerous 
substances, mainly released by adipose tissue such as tumor necrosis factor-alpha 
(TNF-α) are closely linked to each other and are thought to contribute to peripheral insulin   Type 2 Diabetes Mellitus-Induced Hyperglycemia in Patients with NAFLD and Normal LFTs: …   625 
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resistance [10]. In addition, treatment of T2DM with insulin induces accumulation of lipids 
in the liver and skeletal muscle without affecting whole-body insulin sensitivity after near-
normoglycemia for 67 h [11]. 
The main idea of the current research study was to examine the ability of T2DM-induced 
hyperglycemia in enhancing the pathogenicity of NAFLD by induction of oxidative stress 
(hydrogen  peroxide and malondialdehyde) and releasing of inflammatory mediators 
(TNF-α and IL-6) in absence of liver damage as confirmed by the presence of normal liver 
function tests (LFTs). No previous studies measured this pathway in the early stages of 
the disease. Moreover, we aimed to provide a pharmaceutical care plan to chronically ill 
patients who are suffering from NAFLD in conjunction with T2DM. 
Materials and methods 
Patients’ characteristics 
One hundred and five Patients were enrolled in the current study. They were selected from 
the outpatient clinics of Internal Medicine department, Specialized Medical Hospital, 
Mansoura University. Patients' consent was obtained according to the regulations of the 
Egyptian Ministry of Health and the study design was approved by the local ethics 
committee.  
The Inclusion criteria for all participants were:  
(a) age between 40–60 years 
(b) newly diagnosis of NAFLD and/or hyperglycemia or HbA1c level > 7 due to T2DM 
(c) good general health condition other than T2DM or NAFLD.  
The exclusion criteria were: 
(a) history of alcohol ingestion 
(b) malignancy 
(c) previous gastrointestinal tract surgery 
(d) smoking  
(e) presence of any liver disease that can cause fatty liver such as chronic hepatitis C, 
autoimmune liver disease and Wilson’s disease  
(f) ingestion of drugs known to produce hepatic steatosis such as corticosteroids, high-
dose estrogens, methotrexate, valproic acid, tetracycline hydrochloride, amiodarone, 
isoniazide, phenytoin, carbamazepine or tamoxifen citrate in the previous 6 months  
(g) high serum level of ALT, AST or gamma glutamyl transferase (GGT) (> 45 U/l). 
Diagnosis of NAFLD 
Nonalcoholic Fatty Liver Disease was diagnosed by imaging tests, such as ultrasound, 
magnetic resonance imaging (MRI), computerized tomography scan (CT) and magnetic 
resonance elastography. In addition, blood tests were performed to assess liver function 
and to exclude other causes of liver disease. The exclusion of significant alcohol intake 
was essential. Presence of abnormal fat accumulation in the liver found by X-rays and 
ultrasound images confirmed the diagnosis. In very rare instances, a liver biopsy was 
performed.  626  M. E. E. Shams, M. M. H Al-Gayyar, and E. A. M. E. Barakat:   
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Diagnosis of T2DM 
T2DM was diagnosed according to Health Care Guideline, 14th edition: 
http://www.icsi.org/diabetes_mellitus__type_2/management_of_type_2_diabetes_mellitus_
_9.html 
Patients with fasting plasma glucose level ≥7.0 mmol/l and 2-h postload plasma glucose 
level ≥11.1 mmol/l on a 75-g oral glucose tolerance test were diagnosed as having type 2 
diabetes. Because of the age range of the study population, all cases of diabetes were 
diagnosed after the age of 40 years and were thus classified as type 2 diabetes. 
Study design 
Patients were classified into two groups, the first one (Group A) consists of patients 
suffering from NAFLD and the second group (Group B) consists of patients with NAFLD 
with normal liver function tests (LFTs) in conjunction with hyperglycemia due to T2DM. All 
prospective patients were subjected to patient history taking (personal, past and family 
history) as well as physical examinations. All subjects were interviewed for completion of a 
standardized questionnaire regarding personal medical history, current treatments, and 
life-style behaviors (see:  http://www.signaturehealth.net/documents/OBGYNHP/… 
HistoryNew.pdf). Clinical parameters were also recorded including age, weight, height, hip 
and waist measurements and blood pressure. Body mass index (BMI) and waist/hip ratio 
(WHR) were also calculated. Safety parameters were assessed during clinic visit. Any 
patient who developed serious adverse effects, including heart or hepatic failure, or any 
episode of severe hypoglycemia, was excluded from the study. 
Assessment of medication adherence 
Patients' adherence to medication was assessed using the Measure Treatment Adherence 
(MTA) Scale developed by Delgado and Lima [12].  
Analysis of clinical laboratory and biochemical parameters 
Venous blood samples were obtained from patients after overnight fasting (12 h). Serum 
ALT, AST and GGT were analyzed using commercially available kits. Serum TGs, Choles-
terol and HDL-cholesterol were determined by commercially available kits from Human 
Company. Serum LDL-cholesterol was calculated by the equation of Friedewald [13]. 
The insulin resistance (HOMA IR) was calculated using the formula of Mathews [14]: 
HOMA IR = (fasting insulin X fasting plasma glucose) /22.5 (in case of glucose 
concentration mmol/l and 405 in case of glucose concentration mg/dl). 
Leucocytic hydrogen peroxide concentration was measured by horseradish peroxidase 
(HRPO) method after modification as described previously by Al-Gayyar [15]. This method 
depends on the HRPO mediated oxidation of phenol red by H2O2  released from 
leucocytes, which resulted in the formation of a compound that could be read at 610nm. 
Serum MDA was measured by thiobarbituric acid method using Al-Gayyar’s modifications 
[15]. In brief, serum proteins are precipitated by the addition of trichloroacetic acid. Then, 
thiobarbituric acid reacts with MDA to form thiobarbituric acid-reactive substance that is 
measured  at 532 nm. Serum TNF-α  level  was  analyzed  using  commercially  available   Type 2 Diabetes Mellitus-Induced Hyperglycemia in Patients with NAFLD and Normal LFTs: …   627 
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ELISA kits from BioSource International Inc, Calif, USA. Serum IL-6 was estimated by 
Pelikine Compact Human IL6 ELISA Kit 
Data management and statistical analysis 
Mean values ± standard  error (SE) was used for statistical computations using the 
computer software GraphPad InStat version 3.00, GraphPad Software, San Diego 
California USA. For group comparison ANOVA and Tukey-Kramer Multiple Comparisons 
Test was calculated. Statistical significance was predefined as P ≤0.05.  
Results and Discussion 
Clinical characteristics of the patients' population were summarized in table 1. Patients in 
group A and group B showed comparable age, blood pressure, body mass index and liver 
enzymes. The only difference which was found is that patients in group B had significant 
higher fasting blood glucose levels and insulin resistance compared with patients in 
group A.  
Tab. 1.  Clinical characteristics of patients with NAFLD in comparison to the patients 
with NAFLD and hyperglycemia due to T2DM. 
Variable (mean±SE) 
Patients with NAFLD 
Without T2DM 
[Group A] (n=58) 
With T2DM 
[Group B] (n=47) 
Age (years)  53.8±4.9  52.7±5.1 
Gender (m/f)  35/23  31/16 
Systolic blood pressure (mm Hg)  122.4±11.2  126.3±9.7 
Diastolic blood pressure (mm Hg)  84.6±4.1  89.4±4.6 
Body mass index (Kg/m
2)  27.8±2.0  29.4±1.8 
Waist/hip ratio  0.92±0.04  0.93±0.07 
ALT (U/l)  30.5±2.8  34.8±3.2 
AST (U/l)  28.4±2.7  28.9±2.1 
GGT (U/l)  24.4±1.7  27.3±2.1 
Fasting glucose (mg/dl)  89.4±7.8  203.6±4.7* 
Fasting insulin (mU/l)  17.3±1.4  19.8±1.7 
HOMA IR  4.1±0.5  9.4±0.79* 
NAFLD…non alcoholic fatty liver disease; T2DM…type 2 diabetes mellitus;  
HOMA insulin resistance (using the formula of Mathews) = 
405
glucose)   plasma   fasting     insulin   (fasting ×
  
* Significant difference at p<0.05. 
 
T2DM induced hyperglycemia alters lipid profile in NAFLD patients with normal 
LFTs 
As shown in table 2, patients in group B showed significant increase in serum levels of 
triglycerides and LDL-C compared with those in group A (p<0.05). Patients in group A and 
group B showed no significant differences in their serum cholesterol level. In addition, 628  M. E. E. Shams, M. M. H Al-Gayyar, and E. A. M. E. Barakat:   
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patients in group B showed significant decrease in serum HDL-C concentration as 
compared with patients in group A (p<0.05).  
Tab. 2.  Lipid profile, oxidative stress and proinflammatory cytokine levels in patients 
with NAFLD in comparison to the patients with NAFLD and hyperglycemia due 
to T2DM.  
Variable (mean±SE) 
Patients with NAFLD 
Without T2DM 
[Group A] (n=58) 
With T2DM 
[Group B] (n=47) 
Cholesterol (mg/dl)  209.4±12.8  221.7±19.6 
Triglycerides (mg/dl)  174.4±10.1  206.7±13.3* 
LDL-C (mg/dl)  144.3±9.7  175.7±7.6* 
HDL-C (mg/dl)  29.7±2.7  21.4±2.1* 
Leukocyte hydrogen peroxide (μM)  81.4±6.2  102.2±3.1* 
Serum MDA (nmol/ml/h)  294.7±11.4  425.5±9.6* 
Serum TNF-α (pg/ml)  11.7±1.2  21.1±0.6* 
Serum IL-6 (pg/ml)  28.2±2.8  40.4±1.0* 
NAFLD…non alcoholic fatty liver disease; T2DM…type 2 diabetes mellitus; LDL…low density lipoprotein; 
HDL…high density lipoprotein; MDA…malondialdehyde; TNF-α…tumor necrosis factor-alpha; IL-
6…interleukin-6. 
* Significant difference at p<0.05. 
 
T2DM is commonly associated with dyslipidemia and hyperglycemia in NAFLD patients 
[7, 16]. Therefore, our study showed significant impaired lipid profile in group B of the 
patients compared with patients in group A. Similar findings were found also by other 
researchers  [7, 17]. Of note, the increased in TG in the patients was associated with 
insulin resistance. However, insulin resistance leads to hepatocytes fat deposition by two 
pathways; lipolysis and hyperinsulinemia. The first mechanism involves the suppression of 
the sensitivity of insulin receptor on lipocyte membrane leading increased free fatty acid 
amount more than the body needs which results in lipid deposition in hepatocytes. In the 
second mechanism, hyperinsulinemia blocks mitochondrial fatty-acid oxidation, resulting in 
a high concentration of intracellular fatty acids leading to oxidative stress [18]. 
T2DM induced hyperglycemia potentiates release of oxidative stress in NAFLD 
patients with normal LFTs 
Patients in group B showed a significant increase in leukocyte level of hydrogen peroxide 
and serum concentration of malondialdehyde (MDA) compared with those in group A, 
p<0.05 (Table 2). In addition, as shown in figure 1 (A and B), there were significant 
positive correlations between plasma glucose level and both leukocyte hydrogen peroxide 
concentration (r=0.63 and p<0.01) and serum MDA concentration (r=0.73 and p<0.01).   Type 2 Diabetes Mellitus-Induced Hyperglycemia in Patients with NAFLD and Normal LFTs: …   629 
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Fig. 1.  Significant positive correlations between plasma glucose level and the following 
parameters: A) leukocyte hydrogen peroxide concentration (r=0.63 and p<0.01), 
B) serum malondialdehyde (MDA) concentration (r=0.73 and p<0.01), C) serum 
tumor necrosis factor alpha (TNF-α) (r=0.68 and p<0.01) and D) serum IL-6 
concentration (r=0.82 and p<0.01.)  
Interestingly, a significant increase in leukocyte level of hydrogen peroxide was found in 
patients of group B compared with patients in group A. There were no previous studies 
that measured the hydrogen peroxide levels in patients with both NAFLD and T2DM. 
However, some previous studies reported an increase in oxidative stress in patients with 
NAFLD and/or T2DM [19–22]. The increase in the oxidative stress can be explained by 
hyperglycemia which can induce oxidative stress by several mechanisms such as glucose 
auto-oxidation, increased nitric oxide synthase activity and FFAs oxidation [19]. The 
accumulated hydrogen peroxide could undergo the Fenton's reaction, generating hydroxyl 
radical, which may lead to lipid peroxidation. The plasma and mitochondrial membrane, 
consists primarily of lipids, are vulnerable to free radical damage and ROS-induced lipid 
peroxidation leading to cell dysfunction and adipose tissue damage resulting in the 
formation of lipid degradation products such as MDA.  
T2DM induced hyperglycemia enhances the release of proinflammatory cytokines in 
NAFLD patients with normal LFTs 
As shown in table 2, patients in group B showed significant increase in serum 
concentrations of TNF-α  and  IL-6 as compared with patients in group A (p<0.05). 
Moreover, significant positive correlations were observed between plasma glucose 630  M. E. E. Shams, M. M. H Al-Gayyar, and E. A. M. E. Barakat:   
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concentration and both serum TNF-α (r=0.68 and p<0.01, Figure 1 (C) and serum IL-6 
concentration (r=0.82 and p<0.01, Figure 1 (D). 
Interestingly, we found a significant increase in serum level of MDA in patients of group B 
compared with those in group A, which is in agreement with the findings in other research 
studies [23, 24]. The produced MDA is a reactive compound, which causes a toxic stress 
in cells and stimulates the release of inflammatory mediators such as TNF-α and IL-6. 
Therefore, we found a significant increase in both markers in patients of group B 
compared with patients in group A. However, no previous studies investigated the levels of 
inflammatory mediators in patients with both T2DM and NAFLD. The increased 
expressions of TNF-α and its receptor have been previously reported in liver and adipose 
tissue in obese individuals with NASH, which correlates with the degree of fibrosis [25]. 
The increased production of inflammatory cytokines in NAFLD could exacerbate systemic 
and hepatic insulin resistance  with worsening inflammation  and  fibrosis. Inflammatory 
cytokines cause impaired insulin signalling, cell damage, neutrophil chemotaxis, hepatic 
stellate cell activation and apoptosis. 
In fact, there is an interactive relationship between oxidative stress markers and 
inflammatory mediators. Increases in TNF expression induce activation of NAD(P)H 
oxidase and production of reactive oxidative species, leading to endothelial dysfunction in 
type 2 diabetes [26]. On the other hand, oxidative stress has also been shown to increase 
production of pro-inflammatory cytokines (TNF-α, TGF-α, IL-6, IL-8) [27, 28].  
It has recently been hypothesized that NAFLD is a consequence of a ‘two hit’ insult. As a 
consequence of insulin resistance, there is excessive accumulation of triglyceride in the 
hepatocytes, this being the first hit. While, oxidative stress and increased inflammatory 
cytokines were considered as the second hit, resulting in hepatocyte injury, inflammation 
and fibrosis [29]. 
Patients' adherence to anti-diabetic medication 
The patients involved in the current study were newly diagnosed with NAFLD either with or 
without hyperglycemia due to T2DM. Patients in group B demonstrated unsatisfactory 
adherence to anti-diabetic medication therapy, dietary/exercise recommendations and 
even appointments to show up at the clinics for the scheduled check up. High fasting blood 
glucose levels [(mean± SE) equal 203.6±4.7 mg/dl)] were found in this group as shown in 
table 1. All of these patients required pharmacological treatment to control their blood 
glucose levels. Of all patients in this group [N= 47(100%)], the majority [N=32 (68.0%)] 
treated with basal insulin [bedtime intermediate-acting insulin (NPH, Lente or Mixtard 
30/70) or bedtime long-acting insulin (Glargine)] as a monotherapy (N=7) or in combination 
with Metformin (N=16) or with Gliclazide MR (N=9). On the other hand, two patients (4.2%) 
treated with Metformin monotherapy, seven patients treated with Gliclazide MR 
monotherapy (14.9%), four patients (8.5%) treated with a combination therapy of 
Metformin and Gliclazide MR, while two patients only treated with Metformin and 
Pioglitazone (4.2%). 
The majority of patients in group B either treated with insulin monotherapy or with a 
combination therapy of insulin with an oral hypoglycemic agent (OHA) because these 
patients were inadequately controlled with monotherapy of OHA. Despite the pharmaco-  Type 2 Diabetes Mellitus-Induced Hyperglycemia in Patients with NAFLD and Normal LFTs: …   631 
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logical treatment in this group of patients, hyperglycemia was found. This may be due to 
irregular monitoring of blood glucose level and/or due to unsatisfactory adherence to 
medication therapy, dietary/exercise and even appointment to show up at the clinics for 
the scheduled check up. An improvement with medication adherence may be achieved 
through continuing patient education about the disease encouraging patients to monitor 
their blood glucose level regularly [30].  
Two goals are present as a strategy in treatment of patients who are suffering from NAFLD 
in conjunction with T2DM to improve the quality of life and prolong the survival. The 
primary target is to encouraging them to change their lifestyles and strength self-
monitoring through patient education by clinicians. This includes: ingestion of a healthy 
food containing a low carbohydrate and low-fat balanced diet, a reduction of drinks 
containing sugar, saturated fat and trans-fat intake, an increase in dietary fiber content, 
taking moderate aerobic exercise at least 4 times per week, moderate weight reduction. In 
addition regular measuring and monitoring of blood glucose levels and LFTs at which 
glycated hemoglobin (HbA1C) should ideally be brought to < 7 [31]. The secondary target 
is to reduce liver fat deposition and avoid the development NASH, cirrhosis or liver cancer 
and their related complications. Liver protective and anti-inflammatory drugs may be 
beneficial drugs in these patients to  prevent and treat steatohepatitis and advanced 
fibrosis [32]. One to two kinds of liver protective, antioxidant and anti-inflammatory drugs 
such as polyene phosphatidylcholine, silymarin, glycyrrhizin, bicyclol, vitamin E, ursode-
oxycholic acid and S-ademetionine, insulin sensetizer could be used, according to the 
disease activity, the stage of the disease, drug efficacy and the cost of treatment [33]. 
Conclusion 
From the previous results, we can conclude that:  
1) T2DM induced hyperglycemia may enhance the pathogenicity of NAFLD by increasing 
triglycerides, LDL-C and glucose formation.  
2) Hyperglycemia in T2DM enhances the formation of oxidative stress markers and 
inflammatory mediators triggering cell dysfunction.  
3) The release of inflammatory mediators in patients who are suffering from both T2DM 
and NAFLD occurs in an early stage of the disease even before liver damage. Diabetes 
educators and clinicians should emphasize the benefits of a healthy lifestyle, regular 
monitoring of blood glucose levels, HbA1c and lipid profile especially in patients who are 
suffered from NAFLD to protect them against a progressive liver damage. 
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